公开(公告)号：US20190338015A1

公开(公告)日：2019-11-07

申请号：US16342139

申请日：2017-10-19

申请人： CELLECTIS

发明人： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Laurent POIROT ,  Murielle DERRIEN ,  Donna Marie STONE ,  Javier Fernando CHAPARRO RIGGERS

IPC分类号： C07K14/705 ,  C12N5/0783 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28

摘要： The invention relates to cell death inducing chimeric antigen receptors (D-CAR). In particular, the present invention relates to cell death inducing chimeric antigen receptors which comprise at least one death domain in their endodomain, including cell death inducing chimeric antigen receptors comprising within their death domains modifications which attenuate the self-association and/or binding to pro-apoptotic or pro-necrotic adaptor proteins, such as FADD or TRADD. Moreover, the present invention relates to an engineered immune cell expressing at its surface a cell death inducing CAR of the present invention and, optionally, an activating chimeric antigen receptor, wherein the extracellular ligand-binding domains of the cell death inducing CAR and the activating CAR bind to different antigens. The engineered immune cell may furthermore comprise at least one edited (e.g., inactivated) gene selected from TCR genes, immune check point genes, genes involved in drug resistance, and combinations thereof.

公开(公告)号：US20240189354A1

公开(公告)日：2024-06-13

申请号：US18393322

申请日：2023-12-21

申请人： CELLECTIS SA

发明人： Julianne SMITH ,  Phillippe DUCHATEAU ,  Murielle DERRIEN

IPC分类号： A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

摘要： The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.